Constipation and GLP-1 Medications: What You Need to Know Before Symptoms Start

Constipation is a common but often overlooked side effect in people taking GLP-1 receptor agonists, a class of medications widely used to treat obesity and type 2 diabetes. These drugs, which include semaglutide and tirzepatide, are very effective for weight loss and blood sugar control. However, they also affect how the digestive system works. Constipation occurs in about 17–24% of patients taking GLP-1 receptor agonists and can become uncomfortable enough that some people stop taking the medication. Because of this, constipation should be managed proactively rather than waiting until symptoms become severe. 

GLP-1 receptor agonists slow down how quickly food moves through the stomach and intestines. This process, called delayed gastric emptying, helps people feel full longer and eat less. At the same time, these medications may reduce thirst signals, causing people to drink less water without realizing it. Slower digestion, reduced fluid intake, and changes in gut movement all work together to increase the risk of constipation. This means the problem is not caused by just one factor, but by several changes happening at the same time. 

Education before starting therapy is one of the most important steps in preventing constipation. Patients should be told ahead of time that stomach and bowel side effects are common and expected. Knowing what to expect makes symptoms less alarming and helps people stick with treatment. Patients should also be taught simple strategies to reduce side effects, such as drinking more fluids, increasing fiber slowly, and adjusting food choices when symptoms flare. When people feel prepared, they are more likely to stay on the medication and benefit from it long term. 

Lifestyle changes are the first line of treatment for constipation in patients taking GLP-1 receptor agonists. Adequate hydration is critical. Most patients should aim for more than 2 to 3 liters of fluid per day unless their doctor has told them otherwise. Because thirst may be reduced, people may need to drink on a schedule rather than waiting until they feel thirsty.  

Dietary fiber is another cornerstone of treatment, but it must be increased slowly. Adding too much fiber too fast can worsen bloating and discomfort. Both soluble and insoluble fiber are helpful. Foods like prunes, dried apricots, berries, vegetables, whole grains, and legumes can support regular bowel movements. Prunes and dried fruits are especially effective because they contain natural sugars that draw water into the stool. Fiber supplements, such as psyllium, can also be helpful when food intake is limited. 

Food choices also matter. Meals with higher water content, lower viscosity, and a lower glycemic index tend to move through the stomach more easily. During periods of constipation, it may help to temporarily limit very high-protein or high-fat meals, which can slow digestion even more. Regular physical activity, even simple walking, also helps stimulate bowel movements and supports overall gut health. 

A study published in JAMA emphasized the importance of hydration and fiber when managing constipation in patients taking GLP-1 receptor agonists. The authors noted that delayed gastric emptying and reduced thirst may require more active treatment with bulk-forming laxatives like psyllium, stool softeners such as docusate sodium, or osmotic or stimulant laxatives like polyethylene glycol. This highlights that lifestyle changes are often necessary but may not always be enough on their own. 

Special care is needed for older adults taking GLP-1 receptor agonists. This group is at higher risk for dehydration, excessive weight loss, muscle loss, and vitamin or mineral deficiencies. Constipation in older adults can also lead to complications such as fecal impaction or bowel obstruction. The American Diabetes Association notes that GLP-1 receptor agonists are not preferred in patients with severe constipation, significant gastroparesis, or recurrent bowel blockage. Close monitoring and early intervention are essential in this population.  

In some patients, constipation may not be caused by slow digestion alone. Pelvic floor dysfunction, which affects how the muscles involved in bowel movements work, can also play a role. Pelvic floor physical therapy can be very effective in these cases, especially when standard treatments do not help. This type of therapy focuses on retraining the muscles to relax and coordinate properly during bowel movements. Although no diagnostic guidelines exist specifically for GLP-1-related constipation, standard tests such as anorectal manometry and the balloon expulsion test can help identify patients who may benefit from this therapy. 

Pelvic floor therapy using rehabilitative ultrasound is considered the most effective treatment for constipation caused by defecatory disorders, with success rates as high as 80%. Studies show that it works far better than laxatives and lifestyle changes alone for these patients. Multimodal physical therapy programs that combine muscle training, education, and physical activity have also shown strong improvements in symptoms and quality of life, with high patient satisfaction and no reported safety concerns. 

Overall, constipation in patients taking GLP-1 receptor agonists is common, predictable, and manageable. Proactive education, slow dose increases, lifestyle changes, and early use of supportive treatments can prevent symptoms from becoming severe. When constipation is addressed early and thoughtfully, patients are more likely to stay on therapy and achieve lasting benefits for weight and metabolic health. 

---

Disclaimer: This blog is here for your help. It is the opinion of a Licensed Physical Therapist. If you experience the symptoms addressed you should seek the help of a medical professional who can diagnose and develop a treatment plan that is individualized for you.